TY - JOUR
KW - adverse effects
KW - Analgesics, Opioid/administration & dosage/adverse effects
KW - Bunavail
KW - Buprenorphine/administration & dosage/adverse effects
KW - Delayed-Action Preparations
KW - Dosage
KW - Drug Abuse
KW - Drug Administration Schedule
KW - Drug Interactions
KW - Efficacy
KW - Humans
KW - Injections, Subcutaneous
KW - naloxone
KW - Opiate Substitution Treatment/adverse effects/methods
KW - opioid dependence
KW - Opioid-Related Disorders/diagnosis/drug therapy/psychology
KW - Pregnancy
KW - Probuphine
KW - Safety
KW - Severity of Illness Index
KW - Suboxone
KW - Treatment Outcome
KW - Zubsolv
BT - The Medical letter on drugs and therapeutics
C5 - Opioids & Substance Use
CP - 1541
CY - United States
IS - 1541
JF - The Medical letter on drugs and therapeutics
PP - United States
PY - 2018
SN - 1523-2859; 0025-732X
SP - 35
EP - 37
EP - 
T1 - Once-monthly subcutaneous buprenorphine (Sublocade) for opioid use disorder
T2 - The Medical letter on drugs and therapeutics
TI - Once-monthly subcutaneous buprenorphine (Sublocade) for opioid use disorder
U1 - Opioids & Substance Use
U2 - 29485976
VL - 60
VO - 1523-2859; 0025-732X
Y1 - 2018
ER -